Even more interesting is our observation that inhibition of RORγ in combination with ATV, an agent that is widely used and overall well-tolerated in the context of cardiovascular diseases, significantly reduced SREBF2 gene expression. The gene discussed is RORC; the disease is cardiovascular disorder.